RBC Capital Maintains Outperform on Biohaven, Raises Price Target to $68
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Leonid Timashev has maintained an 'Outperform' rating on Biohaven (NYSE:BHVN) and raised the price target from $59 to $68.
September 24, 2024 | 12:46 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital has reaffirmed its 'Outperform' rating for Biohaven and increased the price target to $68, indicating confidence in the company's future performance.
The increase in price target from $59 to $68 by RBC Capital suggests a positive outlook on Biohaven's future performance. This is likely to boost investor confidence and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100